Increased Demand Causes Fuji to Expand Astaxanthin Production


The plan is to double current production capacity.

Fuji Chemical Industry Company, Ltd., (Toyama, Japan) announced plans to double production of its AstaReal natural astaxanthin (Haematococcus pluavialis) in response to increased demand worldwide, the company says. Production will ramp up at Fuji’s wholly owned subsidiary BioReal AB in Gustavsberg, Sweden.

The company says demand has been driven by increasing science supporting AstaReal’s “positive effects on health,” along with AstaReal’s GRAS approval in the United States last year.

The company says that production at the BioReal facility can be expanded rapidly. The plan is to double current production capacity.

Related Videos
Nils Hoem and Nutritional Outlook editor Sebastian Krawiec
Related Content
© 2024 MJH Life Sciences

All rights reserved.